RHON-KLINIKUM AG (RHK) AI Stock Analysis

• Market Cap: €883.59M
• Dividend Yield: 0.77%
• Average Volume (3M): 955.00
• Price to Earnings (P/E): 23.2
• Beta (1Y): -0.05
• Revenue Growth: 9.10%
• EPS Growth: -15.07%
• Country: DE
• Employees: 18,819
• Sector: General
• Sector Strength: N/A
• Industry: Medical - Care Facilities
• EPS (TTM): 0.15
• Shares Outstanding: 66,962,470
• 10 Day Avg. Volume: 528
• 30 Day Avg. Volume: 955
• PEG Ratio: 1.78
• Price to Book (P/B): 0.72
• Price to Sales (P/S): 0.58
• P/FCF Ratio: 16.27
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 0.54
• Revenue Forecast (FY): €1.46B

• Rating: 70 Outperform
• Price Target: €14.50 ▲(12.40% Upside)

The overall stock score of 70 reflects RHON-KLINIKUM AG's solid financial performance, which is the most significant factor. The technical analysis indicates moderate market conditions, while the valuation suggests the stock is fairly priced. The absence of earnings call and corporate events data means these factors did not influence the score.

Positive Factors

Strong balance sheet

Low leverage and a high equity base reduce solvency risk and increase financial flexibility. This foundation supports sustained capital spending on hospitals and technology, enables strategic M&A or partnerships, and cushions the company against cyclical pressures over months.

Improved cash generation

Rising free cash flow and a robust operating cash flow to net income ratio indicate the business can fund operations and reinvest internally. Strong cash conversion reduces reliance on external financing and supports long-term capex, working capital, and resilience to shocks.

Stable margins and rising net profit

Consistent gross and operating margins with improving net margin signal effective cost control and pricing/payer management. Sustained margin stability enhances long-term profitability, enabling reinvestment in care quality and capacity without eroding cash generation.

Negative Factors

Inconsistent revenue growth

Uneven top-line trends impair predictability of patient volumes and reimbursement receipts. This complicates capacity planning, resource allocation, and multi-period budgeting, potentially pressuring margins and cash flow reliability absent clearer secular demand drivers.

Declining EPS trend

Material negative EPS growth points to profit pressures that could reflect rising costs or episodic revenue weakness. If persistent, lower earnings per share limit retained earnings for reinvestment and reduce buffer for funding strategic initiatives or weathering reimbursement shocks.

Dependence on insurance reimbursements

High dependence on payer reimbursement exposes revenues and margins to regulatory changes and negotiated rate shifts. Reimbursement policy adjustments or payer negotiating leverage can have lasting impact on revenues and unit economics over multiple quarters.

RHON-KLINIKUM AG Business Overview & Revenue Model

Company Description

RHÖN-KLINIKUM Aktiengesellschaft, together with its subsidiaries, offers in-patient, semi-patient, and outpatient healthcare services in Germany. Its hospitals offer treatment services, including rehabilitation of cardiovascular patients, hand surgery, neurological, psychosomatic, addiction therapy facilities, ophthalmology, trauma surgery, dentistry, thoracic, pulmonary, vascular, tumors, neurological conditions, and treatment of spinal column, joints, and heart diseases. It operates eight hospitals and 5,420 beds/places at five medical sites. The company is based in Bad Neustadt an der Saale, Germany.

How the Company Makes Money

RHON-KLINIKUM AG generates revenue primarily through the provision of healthcare services to patients, which includes inpatient and outpatient treatments. The company is reimbursed by health insurance providers for the medical services rendered, which constitutes a significant portion of its revenue. Additional revenue streams include partnerships with pharmaceutical companies for clinical trials and research, as well as specialized programs and services that cater to niche markets within the healthcare sector. RHK's focus on efficiency and patient satisfaction enhances its ability to attract and retain patients, further contributing to its financial performance.

RHON-KLINIKUM AG Financial Statement Overview

Summary

RHON-KLINIKUM AG exhibits solid financial health with strengths in its balance sheet and cash flow management. The income statement shows stable margins, although revenue growth has been uneven. The company maintains a strong equity position, low leverage, and improved cash flow measures, positioning it well in the healthcare providers & services industry.

Income Statement

The company's income statement shows moderate financial health with a steady gross profit margin over the years. The net profit margin improved from 1.8% in 2020 to 2.8% in 2023, highlighting an upward trend in profitability. However, the revenue growth rate has been inconsistent, showing a decline in 2023 compared to 2022. The EBIT and EBITDA margins have remained stable, indicating efficient operational management.

Balance Sheet

The balance sheet reflects a strong financial position with a low debt-to-equity ratio, demonstrating prudent financial management. The equity ratio has remained stable, showcasing a solid foundation. The return on equity has improved, signifying enhanced profitability. The company's high equity base relative to its total assets suggests financial stability and lower leverage risk.

Cash Flow

Cash flow analysis reveals a positive trajectory with improved free cash flow growth, indicating better cash generation capabilities. The operating cash flow to net income ratio is robust, highlighting efficient cash management. The free cash flow to net income ratio has shown significant improvement, reflecting enhanced capability to generate cash from operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.65B	1.60B	1.73B	1.45B	1.40B	1.36B
Gross Profit	499.52M	171.82M	202.88M	999.52M	182.63M	937.72M
EBITDA	115.77M	122.23M	116.58M	106.15M	100.21M	80.66M
Net Income	37.68M	43.35M	38.71M	25.14M	28.30M	1.45M
Balance Sheet
Total Assets	1.87B	1.86B	1.77B	1.70B	1.67B	1.63B
Cash, Cash Equivalents and Short-Term Investments	346.19M	426.66M	342.84M	296.33M	292.12M	257.36M
Total Debt	146.87M	149.60M	149.84M	158.20M	159.76M	160.60M
Total Liabilities	535.79M	530.51M	490.30M	453.51M	440.82M	439.45M
Stockholders Equity	1.30B	1.30B	1.25B	1.22B	1.20B	1.17B
Cash Flow
Free Cash Flow	0.00	57.20M	46.20M	-16.90M	19.70M	16.30M
Operating Cash Flow	0.00	127.60M	109.00M	60.30M	97.50M	113.30M
Investing Cash Flow	0.00	-50.40M	40.90M	-105.20M	-58.30M	-135.20M
Financing Cash Flow	0.00	-3.30M	-21.20M	-4.10M	-3.90M	-15.10M

RHON-KLINIKUM AG Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 12.90
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:RHK, the sentiment is Positive. The current price of 12.9 is below the 20-day moving average (MA) of 13.05, above the 50-day MA of 12.79, and above the 200-day MA of 12.36, indicating a bullish trend. The MACD of 0.13 indicates Negative momentum. The RSI at 62.11 is Neutral, neither overbought nor oversold. The STOCH value of 71.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DE:RHK.

RHON-KLINIKUM AG Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MED	77 Outperform	€184.30M	5.26	15.25%	1.12%	4.90%	―
M12	74 Outperform	€320.89M	17.97	15.61%	2.80%	6.52%	7.17%
LIK	73 Outperform	€132.60M	28.45	23.66%	―	0.21%	7.53%
RHK	70 Outperform	€883.59M	23.19	2.94%	0.77%	9.10%	-15.07%
Sector *	55 Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
MAK	41 Neutral	€20.24M	-1.39	―	―	6.87%	-94.85%